162 related articles for article (PubMed ID: 19459018)
1. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?
Turrini O; Schmidt CM; Moreno J; Parikh P; Matos JM; House MG; Zyromski NJ; Nakeeb A; Pitt HA; Lillemoe KD
J Gastrointest Surg; 2009 Oct; 13(10):1791-7. PubMed ID: 19459018
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.
Smith RA; Ghaneh P; Sutton R; Raraty M; Campbell F; Neoptolemos JP
J Gastrointest Surg; 2008 Aug; 12(8):1422-8. PubMed ID: 18543046
[TBL] [Abstract][Full Text] [Related]
3. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
Ong SL; Garcea G; Thomasset SC; Mann CD; Neal CP; Abu Amara M; Dennison AR; Berry DP
J Gastrointest Surg; 2008 Jun; 12(6):1068-73. PubMed ID: 18043987
[TBL] [Abstract][Full Text] [Related]
4. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
5. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
8. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Preoperative Serum CA19-9 on Margin Status.
Mosquera C; Johnson HM; Mitsakos AT; Neill NE; Bellamy N; Irish W; Zervos EE; Laks S
Am Surg; 2019 Sep; 85(9):965-972. PubMed ID: 31638508
[TBL] [Abstract][Full Text] [Related]
10. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
Ferrone CR; Finkelstein DM; Thayer SP; Muzikansky A; Fernandez-delCastillo C; Warshaw AL
J Clin Oncol; 2006 Jun; 24(18):2897-902. PubMed ID: 16782929
[TBL] [Abstract][Full Text] [Related]
11. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
12. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma.
Rudnicki J; Agrawal AK; Grzebieniak Z; Zukrowski P; Zyśko D; Jelen M; Kielan W; Sebastian M; Słonina J; Marek G; Duda-Barcik Ł
Folia Histochem Cytobiol; 2010 Jan; 48(2):249-61. PubMed ID: 20675282
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
16. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
18. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients.
Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P
Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902
[TBL] [Abstract][Full Text] [Related]
19. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
